OncoMatch/Clinical Trials/NCT06690827
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Is NCT06690827 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Anti-CD123 CAR NK cells for aml (acute myeloid leukemia).
Treatment: Anti-CD123 CAR NK cells — This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: IL3RA positive expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Cannot have received: targeted therapy
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Cannot have received: other experimental drug treatments
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Lab requirements
Blood counts
white blood cells >1.0×10^9/l, neutrophils >0.5×10^9/l, lymphocytes >0.5×10^9/l, platelets >50×10^9/l
Kidney function
serum creatinine ≤2.0×uln
Liver function
alt and ast ≤3.0×uln (for patients with liver invasion ≤5.0×uln); total bilirubin ≤2.0×uln (for patients with gilbert's syndrome ≤3.0×uln)
Cardiac function
echocardiography indicates a left ventricular ejection fraction ≥50%, and no significant abnormalities on electrocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify